News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Long-acting HIV treatment news

Show

From To
Long-acting HIV treatment
Long-acting injectible antiretroviral trial begins

Can a monthly injection of two antiretroviral drugs offer a better chance of suppressing the virus than current oral regimens, among individuals with adherence challenges? A trial that will enroll some 350 volunteers with documented lapses in treatment in the preceding year and a half will seek to find out, the National Institutes of Health announced today.

Published
28 February 2019
From
Science Speaks
Long-acting HIV treatment
Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

Published
30 January 2019
From
Positively Aware
PrEP science
Removable PrEP implant produces high drug levels in rabbits; further studies planned

A small removable plastic implant resembling a tiny piece of dry spaghetti is capable of delivering sustained levels of the drug tenofovir, researchers told last month’s HIV

Published
15 November 2018
By
Gus Cairns
Long-acting HIV treatment
ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

Published
05 November 2018
From
Poz
PrEP science
Beyond Truvada – what is the future of PrEP?

Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate/emtricitabine (Truvada) has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in

Published
31 October 2018
By
Roger Pebody
New and experimental HIV treatments
Long-lasting HIV injection is a step closer after second GSK study

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

Published
31 October 2018
From
Reuters
New and experimental HIV treatments
First large HIV prevention trial using antibodies will probably not be the last

The HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week was dominated by studies of one type of molecule – broadly neutralising antibodies

Published
29 October 2018
By
Gus Cairns
PrEP science
The long tail of injectable PrEP is especially long for women

Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around

Published
25 October 2018
By
Roger Pebody
Long-acting HIV treatment
Wide range of views about switching to weekly, monthly or biannual ART

Two-thirds of people taking combination antiretroviral therapy (cART) would be interested in switching to a once-weekly oral regimen should it become available, according to American research published in

Published
15 October 2018
By
Michael Carter
New and experimental HIV treatments
Long-acting injectable implant shows promise for HIV treatment and prevention

The long-acting antiretroviral drug formulation, developed by UNC School of Medicine researchers, is injected under the skin and forms into a solid implant that dissolves slowly to release anti-HIV medication over time.

Published
09 October 2018
From
University of North Carolina
← Prev12345...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.